MedPath

KAINOS MEDICINE INC

KAINOS MEDICINE INC logo
🇺🇸United States
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

3

Active:0
Completed:2

Trial Phases

2 Phases

Phase 1:2
Phase 2:1

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials

Phase 1
2 (66.7%)
Phase 2
1 (33.3%)

Trial to Evaluate the Efficacy and Safety of KM-819 Treatment to Slow the Progression of Multiple System Atrophy (MSA)

Phase 2
Recruiting
Conditions
Multiple System Atrophy
Interventions
Drug: Placebo
First Posted Date
2023-01-25
Last Posted Date
2024-05-07
Lead Sponsor
Kainos Medicine Inc.
Target Recruit Count
78
Registration Number
NCT05695378
Locations
🇰🇷

CHA Bundang Medical Center, CHA University, Seongnam-si, Gyeonggi-do, Korea, Republic of

Phase I, KM-819 in Healthy Subjects for Parkinson's Disease

Phase 1
Completed
Conditions
Parkinson's Disease
Interventions
Drug: Placebo
First Posted Date
2017-01-18
Last Posted Date
2020-04-13
Lead Sponsor
Kainos Medicine Inc.
Target Recruit Count
88
Registration Number
NCT03022799
Locations
🇰🇷

CHA Bundang Medical Center, CHA University, Seongnam, Gyeonggi-do, Korea, Republic of

Single Ascending Dose (SAD)/Multiple Ascending Dose(MAD) Safety/Pharmacokinetic (PK) Study of KM-023

Phase 1
Completed
Conditions
Human Immunodeficiency Virus
Interventions
Drug: Placebo for KM-023
First Posted Date
2011-05-05
Last Posted Date
2012-07-26
Lead Sponsor
Kainos Medicine Inc.
Target Recruit Count
83
Registration Number
NCT01348516
Locations
🇰🇷

Clinical Trials Center, Seoul National University Hospital, Seoul, Korea, Republic of

News

No news found
© Copyright 2025. All Rights Reserved by MedPath